Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13579-13590

  Mock, Andreas ^a   Warta, Rolf ^a   Geisenberger, Christoph ^a   Bischoff, Ralf ^b,c   Schulte, Alexander ^d   Lamszus, Katrin ^d   Stadler, Volker ^b   Felgenhauer, Thomas ^b   Schichor, Christian ^e   Schwartz, Christoph ^e   Matschke, Jakob ^d   Jungk, Christine ^a   Ahmadi, Rezvan ^a   Sahm, Felix ^c,f   Capper, David ^c,f   Glass, Rainer ^e   Tonn, Jörg Christian ^e   Westpha, Manfred ^d   Von Deimling, Andreas ^c,f   Unterberg, Andreas ^a   Bermejo, Justo Lorenzo ^a,c   Herold Mende, Christel ^a   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b PEPPERPRINT GMBH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f Institute of Pathology   (Germany)

Author keywords

Antibodies; Glioblastoma; Long term survival; Non invasive biomarker; Serum; TNC

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 5; GLIOMA EXPRESSED ANTIGEN 2; ISOCITRATE DEHYDROGENASE 1; MELANOMA ANTIGEN 3; PEPTIDE ANTIBODY; PHD FINGER PROTEIN 3; TENASCIN; TENASCIN C ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG; AUTOANTIBODY; OLIGOPEPTIDE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PREDICTION; PRINTED PEPTIDE MICROARRAY; PROTEIN EXPRESSION; PROTEIN MICROARRAY; RELIABILITY; RETROSPECTIVE STUDY; AMINO ACID SEQUENCE; BLOOD; BRAIN TUMOR; CHEMISTRY; COHORT ANALYSIS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; AUTOANTIBODIES; BRAIN NEOPLASMS; COHORT STUDIES; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROGNOSIS; PROTEIN ARRAY ANALYSIS; SURVIVAL ANALYSIS;

EID: 84931095347     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3791     Document Type: Article

References (48)

1. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-489.
2. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014;15:e395-403.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-466.
4. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu C-J, et al. The Somatic Genomic Landscape of Glioblastoma. Cell 2013;155:462-477.
5. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RGW, Hoadley KA, Hayes DN, et al. Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell 2010;17:13-13.
6. Lohr JJ, Ratliff TT, Huppertz AA, Ge YY, Dictus CC, Ahmadi RR, Grau SS, Hiraoka NN, Eckstein VV, Ecker RCR, Korff TT, Deimling von AA, Unterberg AA, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res 2011;17:4296-4308.
7. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, et al. Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. J Clin Oncol 2010;28:4722-4729.
8. Beckhove P, Warta R, Lemke B, Stoycheva D, Momburg F, Schnölzer M, Warnken U, Schmitz-Winnenthal H, Ahmadi R, Dyckhoff G, Bucur M, Jünger S, Schueler T, et al. Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation. J Clin Invest 2010;120:2230-2242.
9. Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, Dorsch K, Flohr S, Fritsche J, Lewandrowski P, Lohr J, Rammensee HG, Stevanovic S, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012;135:1042-1054.
10. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H, Jadus MR. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res 2007;13:566-575.
11. Kufe DW, Frei E, Holland JF, Pollock RE, Bast RC, Weichselbaum RR. Holland Frei Cancer Medicine 6 Review. Pmph Bc Decker; 2003.
12. Fine HA. New Strategies in Glioblastoma: Exploiting the New Biology. Clin Cancer Res 2015;:1-22.
13. Luna Coronell JA, Syed P, Sergelen K, Gyurján I, Weinhäusel A. The current status of cancer biomarker research using tumour-associated antigens for minimal invasive and early cancer diagnostics. J Proteomics 2012;76 Spec No.:102-115.
14. Bouwman K, Qiu J, Zhou H, Schotanus M, Mangold LA, Vogt R, Erlandson E, Trenkle J, Partin AW, Misek D, Omenn GS, Haab BB, Hanash S. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 2003;3:2200-2207.
15. Kijanka G, Murphy D. Protein arrays as tools for serum autoantibody marker discovery in cancer. J Proteomics 2009;72:936-944.
16. Heo C-K, Bahk YY, Cho E-W. Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. BMB Rep 2012;45:677-685.
17. Stadler V, Felgenhauer T, Beyer M, Fernandez S, Leibe K, Güttler S, Gröning M, König K, Torralba G, Hausmann M, Lindenstruth V, Nesterov A, Block I, et al. Combinatorial Synthesis of Peptide Arrays with a Laser Printer. Angew Chem Int Ed 2008;47:7132-7135.
18. Hegi ME, Rajakannu P, Weller M. Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr Opin Neurol 2012;25:774-779.
19. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner H-H. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 2002;98:362-369.
20. Campos B, Centner F-S, Bermejo JL, Ali R, Dorsch K, Wan F, Felsberg J, Ahmadi R, Grabe N, Reifenberger G, Unterberg A, Burhenne J, Herold-Mende C. Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas. The American Journal of Pathology 2011;178:1953-1964.
21. Sahin UU, Koslowski MM, Türeci OO, Eberle TT, Zwick CC, Romeike BB, Moringlane JRJ, Schwechheimer KK, Feiden WW, Pfreundschuh MM. Expression of cancer testis genes in human brain tumors. Clin Cancer Res 2000;6:3916-3922.
22. Fischer U, Struss AK, Hemmer D, Pallasch CP, Steudel WI, Meese E. Glioma-expressed antigen 2 (GLEA2): a novel protein that can elicit immune responses in glioblastoma patients and some controls. Clin Exp Immunol 2001;126:206-213.
23. Pallasch CPC, Struss A-KA, Munnia AA, König JJ, Steudel W-IW, Fischer UU, Meese EE. Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer 2005;117:456-459.
24. Struss AK, Romeike BFM, Munnia A, Nastainczyk W, Steudel WI, König J, Ohgaki H, Feiden W, Fischer U, Meese E. PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme. Oncogene 2001;20:4107-4114.
25. Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Letters 2005;244(2):143-163.
26. Ventimiglia JB, Wikstrand CJ, Ostrowski LE, Bourdon MA, Lightner VA, Bigner DD. Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol 1991;36:41-55.
27. Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou M-F, Ionescu M-CS, Zweifel C, Tolnay M, Wasner M, Mergenthaler S, Miserez AR, Kiss R, Lino MM, et al. Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res 2009;69:458-465.
28. Sarkar S, Nuttall RK, Liu S, Edwards DR, Yong VW. Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res 2006;66:11771-11780.
29. Hirata E, Arakawa Y, Shirahata M, Yamaguchi M, Kishi Y, Okada T, Takahashi JA, Matsuda M, Hashimoto N. Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue. Cancer Science 2009;100:1451-1459.
30. Huang J-Y, Cheng Y-J, Lin Y-P, Lin H-C, Su C-C, Juliano R, Yang B-C. Extracellular matrix of glioblastoma inhibits polarization and transmigration of T cells: the role of tenascin-C in immune suppression. J Immunol 2010;185:1450-1459.
31. Spenlé C, Saupe F, Midwood K, Burckel H, Noel G, Orend G. Tenascin-C: exploitation and collateral damage in cancer management. Cell Adh Migr 2015;:0.
32. Talasila KM, Soentgerath A, Euskirchen P, Rosland GV, Wang J, Huszthy PC, Prestegarden L, Skaftnesmo KO, Sakariassen PO, Eskilsson E, Stieber D, Keunen O, Brekka N, et al. EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol 2013;125:683-698.
33. Swindle CS, Tran KT, Johnson TD, Banerjee P, Mayes AM, Griffith L, Wells A. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. The Journal of Cell Biology 2001;154:459-468.
34. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 2003;98:2430-2439.
35. Catania C, Maur M, Berardi R, Rocca A, Di Giacomo AM, Spitaleri G, Masini C, Pierantoni C, González-Iglesias R, Zigon G, Tasciotti A, Giovannoni L, Lovato V, et al. The tumour-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumours and expansion into patients with metastatic breast cancer. Cell Adh Migr 2015;:0-00.
36. Verschuere T, Van Woensel M, Fieuws S, Lefranc F, Mathieu V, Kiss R, Van Gool SW, De Vleeschouwer S. Altered galectin-1 serum levels in patients diagnosed with high-grade gliom. J Neurooncol 2013;
37. Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, Vrinda M, Arivazhagan A, Balasubramaniam A, Hegde AS, Chandramouli BA, Santosh V, Rao MRS, Kondaiah P, et al. Identification of Potential Serum Biomarkers of Glioblastoma: Serum Osteopontin Levels Correlate with Poor Prognosis. Cancer Epidemiology Biomarkers & Prevention 2010;19:1409-1422.
38. Chen L-C, Zhang H-Y, Qin Z-Y, Wang Y, Mao Y, Yao Y, Zhou L-F. Serological Identification of URGCP as a Potential Biomarker for Glioma. CNS Neurosci Ther 2013;20:301-307.
39. Borg N, Guilfoyle MR, Greenberg DC, Watts C, Thomson S. Serum albumin and survival in glioblastoma multiforme. J Neurooncol 2011;105:77-81.
40. Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad KS, Sheldon J, Tarelli E, Howe FA, Bell BA, Papadopoulos MC. Serum 2-HS Glycoprotein Predicts Survival in Patients with Glioblastoma. Clinical Chemistry 2008;54:713-722.
41. Crocker M, Ashley S, Giddings I, Petrik V, Hardcastle A, Aherne W, Pearson A, Anthony Bell B, Zacharoulis S, Papadopoulos MC. Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro Oncol 2010;13:99-108.
42. Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, Deimling von A, Weller M, Weller M. Longterm survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 2013;19:5146-5157.
43. Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, Gietzelt J, Hentschel B, Westphal M, Simon M, Schackert G, Schramm J, Matschke J, et al. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. Int J Cancer 2014;:n/a-n/a.
44. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013;19:764-772.
45. Verhaak RGWR, Hoadley KAK, Purdom EE, Wang VV, Qi YY, Wilkerson MDM, Miller CRC, Ding LL, Golub TT, Mesirov JPJ, Alexe GG, Lawrence MM, O'Kelly MM, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
46. Yan HH, Parsons DWD, Jin GG, McLendon RR, Rasheed BAB, Yuan WW, Kos II, Batinic-Haberle II, Jones SS, Riggins GJG, Friedman HH, Friedman AA, Reardon DD, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-773.
47. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2008;4:e7752-e7752.
48. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DTW, Collins VP. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009;11:341-347.